Mikrobiom im Gastrointestinaltrakt
Mikrobiom im Gastrointestinaltrakt
AG Schulz
The microbial contribution to pre-cancerous changes of the stomach
The team focuses on the bacterial communities and their contribution to the onset of diesease. The emphasis is the upper gastrointestinal tract regarding the influence of the hosts’ microbiota on the infection with the obligatory pathogen Helicobacter pylori. The acceleration of pre-cancerous changes in the stomach by bacteria could be shown in animal models; we could add indications for humans from in vivo data. Additionally, the influence of the virome to H. pylori infections is investigated.
The mucosal milieu of the gastrointestinal tract
The characterization of the mucosal milieu for different degrees of severity of H. pylori induced gastritis aims to delineate the interaction between the pathogen, the local microbiota, and the host, and thereby identifying possibilities of interventions to stop the advancement of malignal transformations. One of the main focuses lies on the bacterial metabolites as well as the interaction between the bacteria and the immune cells of the host.
Genome-based predictions of antibiotic resistance in H. pylori
Within the scope of the Bavarian Research Network, we are building a database that includes the genotypic as well the phenotypic data about H. pylori, including informations regarding the site of infection (e.g. inflammatory parameter, microbiome signatures, etc.). The collected data will be used to develop an algorithm to predict antibiotic resistances based on sequencing data, enabling to chose the best fitting antibiotic therapy for individual H. pylori infected patients.
(With courtesy of the Bavarian Research Network)
New diagnostic methods to identify H. pylori infections
In translational/clinical project we focus on the diagnostic investigation of pre-cancerous gastric lesions in asymptomatic patients to best stratify those individuals who are under risk to go into endoscopic surveillance. New methods and technology is tested during the endoscopic procedure to get results in an optimized and fast procedure.
Frost F, Kacprowski T, Rühlemann M, Pietzner M, Bang C, Franke A, Nauck M, Völker U, Völzke H, Dörr M, Baumbach J, Sendler M, Schulz C, Mayerle J, Weiss FU, Homuth G, Lerch MM. Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function. Gut. 2021 Mar;70(3):522-530. doi: 10.1136/gutjnl-2020-322753. Epub 2020 Nov 9
Vasapolli R, Schütte K, Schulz C, Vital M, Schomburg D, Pieper DH, Vilchez-Vargas R, Malfertheiner P. Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals. Gastroenterology. 2019 Oct;157(4):1081-1092.e3. doi: 10.1053/j.gastro.2019.05.068.
Schulz C, Schütte K, Koch N, Vilchez-Vargas R, Wos-Oxley ML, Oxley APA, Vital M, Malfertheiner P, Pieper DH. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut. 2018 Feb;67(2):216-225. doi: 10.1136/gutjnl-2016-312904.
Frost F, Kacprowski T, Rühlemann M, Bang C, Franke A, Zimmermann K, Nauck M, Völker U, Völzke H, Biffar R, Schulz C, Mayerle J, Weiss FU, Homuth G, Lerch MM. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Sci Rep. 2019 Dec 27;9(1):20100. doi: 10.1038/s41598-019-56631-4.
Schwahn C, Samietz S, Mundt T, Völzke H, Kocher T, Mayerle J, Holtfreter B, Lerch MM, Biffar R, Schulz C. Reducing uncertainty in estimating associations of oral exposures with Helicobacter pylori serology in the general population. J Clin Periodontol. 2018 Sep;45(9):1056-1068. doi: 10.1111/jcpe.12983.
- Bayresq.net, Bavarian science network, 2020-2022
- DZIF, CEGICLIN (Centre for Gastrointestinal Clinical Studies), 2021-2025
- DZIF,„Microbiota-based biomarkers and interventions against GI infections: Helicobacter pylori eradication effects on GI microbiome signature and reversibility by probiotic supplemention“, 2021-2025
- DZIF, HeliCOPTER, “Determination of local Helicobacter pylori prevalence and antibiotic resistance situation”, 2021-2025
- DZIF translationale Nachwuchs-Forschergruppe Max von Pettenkofer- Institut, LMU- Klinikum der Universität München, 2020- 2024
PD. Dr. med. Christian Schulz
Oberarzt und Arbeitsgruppenleiter
- Einfluss des Viroms des OGI-Traktes auf den Verlauf einer H. pylori -Infektion
- Mikrobielle Signaturen und funktionelle gastrointestinale Erkrankungen
- Mikrobielle Gemeinschaften und ihr Einfluss auf die Entwicklung eines CED- Phänotyps bei genetischen Risikoträgern
- Mukosales Immunmilieu des Magens
Yannick Büchtemann
Assistenzarzt
Nadine Koch, M.Sc.
Mikrobiologin
- Mikrobiomanalytik
- Biostatistik
- Metabolomanalytik
Dr. med. Lukas Macke
Assistenzarzt
- Mukosales Immunmilieu des Magens
- Mikrobielle Gemeinschaften und ihr Einfluss auf die Entwicklung eines CED- Phänotyps bei genetischen Risikoträgern
- Helicobacter pylori
Dr. med. Riccardo Vasapolli
Assistenzarzt
- Intestinales Mikrobiom und Virom bei Gesunden
- Einfluss des Viroms des OGI- Traktes auf den Verlauf einer H. pylori Infektion
- Mikrobielle Signaturen und funktionelle gastrointestinale Erkrankungen
- Endozytoskopie und ihr Einsatz in der Diagnostik präkanzeröser Veränderungen des Magens
Tianjun Song
Medizinischer Doktorand
Theresa Weltermann, cand. med.
Medizinische Doktorandin
- Charakterisierung des immunologischen Milieus des Magens
- Etablierung einer Pipeline zum Multiplex- Staining humaner Biopsien
- Einfluss von Medikamenten auf die gastrale Karzinogenese
Prof. em. Dr. Dr. hc. mult. Peter Malfertheiner
Senior Consultant, ehemaliger Direktor der Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Magdeburg AöR
- Helicobacter pylori
- Mikrobiomforschung
- Hepatozelluläres Karzinom
Renate Artmann
Technische Assistentin
Stephanie Zagler
Technische Assistentin
